Bengaluru-based eNLife Research has secured ₹6 crore in seed funding led by Piper Serica VC Fund to develop an AI-powered blood test for early Alzheimer's detection. The company aims to make neurodegenerative disease diagnosis more accessible in India by moving away from expensive, invasive methods like MRI and PET scans.
Deeptech startup eNLife Research has successfully raised ₹6 crore in a seed funding round led by the Piper Serica VC Fund. This fresh capital is directed toward building a platform capable of detecting Alzheimer's disease and other neurodegenerative conditions through a simple blood-based biomarker test. The company, founded in 2025, plans to use the investment to transition its technology from a prototype phase to clinical-grade validation, while also expanding its research and development team in Bengaluru.
Targeting Early Diagnosis in the Indian Market
The core mission of eNLife is to address the difficulty of late-stage diagnosis. Current standard practices for identifying Alzheimer's often rely on PET scans, MRI scans, or the analysis of cerebrospinal fluid. These methods are frequently expensive, invasive, and typically performed only after significant symptoms have already manifested. The startup aims to provide a diagnostic tool that can be used in routine diagnostic centers, potentially delivering results in two to five hours. By focusing on molecular-stage detection, the company intends to identify risks years before traditional clinical diagnosis is possible.
Research Collaborations and Data Strategy
eNLife is currently building its detection platform by focusing on Indian genetic and lifestyle profiles, which may differ from global datasets often used in standard medical research. To support this, the company has established collaborations with several high-profile institutions, including the Indian Institute of Science, the National Institute of Mental Health and Neurosciences, the Tata Institute of Fundamental Research Hyderabad, and the Centre for Brain Research in Bengaluru. These partnerships are intended to help create comprehensive, India-specific biomarker datasets that are essential for accurate AI-driven diagnostics.
Future Outlook and Execution Risks
Beyond its primary Alzheimer's assay, the startup is working on next-generation tests capable of tracking up to 100 biological markers for various forms of dementia. The company expects to file patents for its biomarker binders, assays, and the detection platform within the next nine to eighteen months. For investors and stakeholders, the key monitorable will be the company's ability to navigate the complex regulatory pathway for medical diagnostics in India. The success of the business will depend on the successful clinical validation of its prototype, securing necessary intellectual property, and demonstrating that its low-cost model can maintain high accuracy compared to current advanced imaging techniques. As the startup is in its early stages of development, future growth will be tied to its execution of these clinical trials and the subsequent commercial adoption of its diagnostic assays.